AZD9550 vs DA-1726

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1/glucagon receptor (dual) · full Obesity pipeline

AZD9550

Developed by AstraZeneca

Phase 2 in Obesitypeptide
Partial signal

NCT06862791 · Phase 2 · completed

The study uses randomization, quadruple blinding, multiple placebo-controlled treatment groups, and includes 377 participants. Its primary endpoints are clinical weight-loss measures, but the results and whether the primary comparisons were met are not yet available, so the evidence cannot be rated as strong.

Next expected readout: January 2027 · NCT06151964 (registry estimate)

No aligned efficacy figure on record for this race.

DA-1726

Developed by MetaVia under a licence from Dong-A ST

Phase 1 in Obesitypeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAZD9550DA-1726
Body weight, % change—Not reported—Not reported
Weight loss of 5% or more—Not reported—Not reported
Weight loss of 10% or more—Not reported—Not reported
Waist circumference, change (cm)—Not reported—Not reported

Body weight, % change

AZD9550
—Not reported
DA-1726
—Not reported

Weight loss of 5% or more

AZD9550
—Not reported
DA-1726
—Not reported

Weight loss of 10% or more

AZD9550
—Not reported
DA-1726
—Not reported

Waist circumference, change (cm)

AZD9550
—Not reported
DA-1726
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

AZD9550: no structured comparison results are available for Obesity.

DA-1726: no structured comparison results are available for Obesity.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AZD9550's landscape · DA-1726's landscape